Comments on: A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants With Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants With Sickle Cell Disease https://scdstudies.com/a-phase-2-3-randomized-multicenter-study-of-gbt021601-administered-orally-to-participants-with-sickle-cell-disease-and-an-open-label-pharmacokinetics-study-in-pediatric-participants-with-sickle-cell/?utm_source=rss&utm_medium=rss&utm_campaign=a-phase-2-3-randomized-multicenter-study-of-gbt021601-administered-orally-to-participants-with-sickle-cell-disease-and-an-open-label-pharmacokinetics-study-in-pediatric-participants-with-sickle-cell Wed, 19 Jun 2024 12:25:21 +0000 hourly 1 https://wordpress.org/?v=6.7.1